Sunniva (XCNQ:SNN) Equity-to-Asset : 0.41 (As of Sep. 2019)

View and export this data going back to 2018. Start your Free Trial

What is Sunniva Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Sunniva's Total Stockholders Equity for the quarter that ended in Sep. 2019 was C$53.67 Mil. Sunniva's Total Assets for the quarter that ended in Sep. 2019 was C$129.89 Mil. Therefore, Sunniva's Equity to Asset Ratio for the quarter that ended in Sep. 2019 was 0.41.

The historical rank and industry rank for Sunniva's Equity-to-Asset or its related term are showing as below:

XCNQ:SNN's Equity-to-Asset is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 0.58
* Ranked among companies with meaningful Equity-to-Asset only.

Sunniva Equity-to-Asset Historical Data

The historical data trend for Sunniva's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sunniva Equity-to-Asset Chart

Sunniva Annual Data

Trend

Dec16

Dec17

Dec18

Equity-to-Asset

0.56

0.46

0.68

Sunniva Quarterly Data
	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19
Equity-to-Asset	Get a 7-Day Free Trial								0.63	0.68	0.60	0.52	0.41

Competitive Comparison of Sunniva's Equity-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Sunniva's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sunniva's Equity-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sunniva's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Sunniva's Equity-to-Asset falls into.

Sunniva Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Sunniva's Equity to Asset Ratio for the fiscal year that ended in Dec. 2018 is calculated as

Equity to Asset (A: Dec. 2018 )	=	Total Stockholders Equity	/	Total Assets
	=	85.013	/	125.32
	=	0.68

Sunniva's Equity to Asset Ratio for the quarter that ended in Sep. 2019 is calculated as

Equity to Asset (Q: Sep. 2019 )	=	Total Stockholders Equity	/	Total Assets
	=	53.673	/	129.886
	=	0.41

Sunniva (XCNQ:SNN) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Sunniva Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Sunniva's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Sunniva (XCNQ:SNN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sunniva Inc (XCNQ:SNN) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

200 Burrard Street, 1200 Waterfront Centre, P.O Box 48600, Vancouver, BC, CAN, V7X 1T2

Website

https://www.sunniva.com

Sunniva Inc is vertically integrated medical cannabis company committed to delivering safe, low-cost, high-quality products and services at scale. The company is focused on the cultivation, production and distribution of therapeutic solutions targeting two of the medical cannabis markets in the world: Canada and California.

Executives

Mark Hamish Kimmins

Director or Senior Officer of Insider or Subsidiary (other than in 4,5,6)